ResMed Inc shares are up 14% in 2 weeks, is it too late to buy?

Quality companies go on sale every now and then.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in sleep apnea device maker ResMed Inc. (CHESS) (ASX: RMD) rose 14% between Tuesday April 15 and Monday’s close, smashing the 2% return from the ASX 200 over the same period.

So what happened?

Put simply, investors appear to have decided that the major question mark hovering over the company’s future performance won’t be so much of an issue after all. Towards the end of April, ResMed reported its financial results for the quarter ended 31 March; a respectable 4% increase in revenue, and a 6% rise in net income. The result was better than the previous quarter’s 2% rise in revenue which had compounded some investors’ worries about the future.

Analysts were concerned that ResMed would struggle to grow revenue in coming years due to the new competitive bidding process in the US that aims to reduce the medical costs. Lower revenue growth was seen as a precursor to what to expect in the future under the new rules. The latest result, and some upbeat commentary appears to have calmed the fears of most.

Short-term noise

What happened to ResMed’s share price over the past six months is a perfect example of short-term market ‘noise’. You’ll note that ResMed’s share price is now above where it was in January, and rising back towards the high it hit in October 2013. These short term fluctuations in the share price offer a buying opportunity for astute investors, however unfortunately this time I didn’t follow my own advice and missed out on the mid-April low.

Still time to buy?

I believe there is. ResMed is a company that always seems expensive, and yet with the incredible record of increasing revenue every quarter since listing in 1995, its current PE ratio of 21 doesn’t seem all that demanding. Some analysts are noting that sales growth in the most recent quarter was a result of discounting, which could reduce future demand, however it’s far too early to make a call on this and the majority of brokers rate the company as either a ‘buy’ or ‘hold’.

Foolish takeaway

ResMed’s share price fall between October 2013 and April 2014 is a classic example of market noise. The best investors use pullbacks like we’ve just seen as a time to add to positions in order to take full advantage of future growth.

Motley Fool contributor Andrew Mudie does not own shares in any companies mentioned. You can find Andrew on Twitter @andrewmudie

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »